SPR 741

Drug Profile

SPR 741

Alternative Names: SPR 741

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northern Antibiotics
  • Developer Evotec AG; Spero Therapeutics
  • Class Antibacterials; Peptides; Polymixins
  • Mechanism of Action Cell membrane structure inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 20 Jul 2018 Antimicrobial data from a preclinical study presented at ASM Microbe (ASMM - 2018)
  • 07 Jun 2018 Preclincial data from a study presented at the ASM Microbe 2018
  • 24 Apr 2018 Updated Antimicrobial data from an in vitro study in Gram-negative infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top